Development and evaluation of a rapid point-of-care test for detecting the hepatitis E virus antigen

作者：Ying, Dong; Hong, Congming; Wen, Guiping; Tang, Zimin; Wang, Siling; Zhang, Xu; Liu, Chang; Ge, Shengxiang^*; Zheng, Zizheng^*; Xia, Ningshao

来源：Clinical Biochemistry, 2018, 55: 89-92.

DOI：10.1016/j.clinbiochem.2018.03.001

• Hepatitis E virus (HEV)
• Antigen
• Point-of-care test
• Fluorescence microbead-based immunoassay
• Enzyme-linked immunosorbent assay (ELISA)

Background: Hepatitis E virus (HEV)-caused acute viral hepatitis is a major threat to public health worldwide. Recently, an enzyme linked immunosorbent assay (ELISA) kit detecting the HEV antigen was reported to have good concordance with the HEV RNA load and showed good clinical performance. But the ELISA kits can barely satisfy the needs of community clinics. In this study, a fluorescent microbead-based immunoassay (FMIA) for detecting the HEV antigen was developed and evaluated. @@@ Methods: A mouse anti-HEV monoclonal antibody (mAb) conjugated with fluorescent microbeads was used as capturing antibody and another mouse mAb was used as detection antibody. Overall, 150 serum samples were collected from HEV-infected patients (n = 50) and non-HEV cases (n = 100) to evaluate the performance of the FMIA. @@@ Results: The FMIA results showed a strong linear correlation with the viral RNA load. The diagnostic sensitivity and specificity of the HEV antigen FMIA were 92.0% (46/50) and 100.0% (100/100), respectively, and the test was consistent (kappa = 0.937, p = 0.627) with the commercial HEV antigen ELISA. The FMIA also showed good consistency with the PCR results (kappa = 0.939, p = 0.134). @@@ Conclusions: As a rapid point-of-care (POC) test, a FMIA that is developed with acceptable performance is suitable for acute hepatitis E diagnosis, especially in developing countries and regions, because of its reduced time and simplified operation.

• 出版日期2018-5
• 单位厦门大学